Tagamet (Cimetidine) - complete drug information

Tagamet (Cimetidine) is an H2-receptor blocker that suppresses acid secretion. It is used to treat the following conditions:

  • For the short term treatment of active duodenal ulcer
  • For the treatment of active benign gastric ulcer.
  • Treatment of erosive gastroesophageal reflux disease (GERD).
  • Treatment of pathological hypersecretory conditions like Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas.
  • Relief and prevention of heartburn and sour stomach as OTC medicine only

Off-Label uses include:

  • Bladder pain syndrome or Interstitial cystitis
  • Prophylaxis of stress ulcers in critically ill patients

Tagamet (Cimetidine) Dose in Adults

  • Tagamet (Cimetidine) for active Duodenal ulcer:
    • 300 mg four times a day, or
    • 800 mg at bedtime ( Higher doses of 1600 mg may be used at bedtime for four weeks in patients with larger duodenal ulcers and smokers)
    • 400 mg twice daily for 8 weeks
  • Prophylactic treatment of Duodenal ulcer:
    •  400 mg at bedtime
  • Dose in Active Gastric ulcer:
    • 300 mg 4 times a day or 800 mg at bedtime for up to 8 weeks
  • Gastroesophageal reflux disease:
    • 400 mg 4 times a day or 800 mg every 12 hourly for 12 weeks
  • OTC labeling of Heartburn:
    • For Prevention of heartburn:
      • 200 mg daily 30 minutes taking a meal that may cause heartburn
    • For symptomatic relief:
      • 200 mg daily to a maximum dose of 400 mg per 24 hours.
  • Off-label use in Interstitial cystitis (bladder pain syndrome):
    • 200 mg thrice daily
  • Off-label use in critically ill patients for Stress ulcer prophylaxis:
    • 300 mg 4 times a day administered via NG tube or orally

Tagamet (Cimetidine) Dose in Childrens

Tagamet (Cimetidine) dose in Gastroesophageal reflux disease:

  • Infants, Children, and Adolescents less than 16 years of age:
    • 20 to 40 mg/kg/day in 3 or 4 divided doses to a maximum dose of 400 mg per dose
  • Adolescents older than16 years of age:
    • 400 mg 4 times a day or 800 mg twelve hourly for 12 weeks

Treatment and maintenance of Duodenal ulcer:

  • Children older than 5 years and Adolescents less than 16 years:
    • 20 to 40 mg/kg/day in 3 or 4 divided doses for 4 - 8 weeks, followed by 5 -- 8 mg/kg/dose once a day at bedtime.
  • Adolescents older than 16 years of age:
    • 300 mg 4 times a day or
    • 800 mg at bedtime or
    • 400 mg twelve hourly for up to 8 weeks

Tagamet (Cimetidine) for Prophylaxis Duodenal ulcer:

  • Adolescents older than 16 years of age:
    • 400 mg at bedtime

Active Gastric ulcer:

  • Adolescents older than 16 years of age:
    • 300 mg 4 times a day or 800 mg at bedtime for up to 8 weeks

Hypersecretory conditions like Zollinger-Ellison syndrome:

  • Adolescents older than 16 years:
    • 300 mg 4 times a day to a maximum daily dose of 2,400 mg/day.

Tagamet (Cimetidine) OTC labeling of Heartburn:

  • For Prevention of heartburn:
    • Children older than 12 years and Adolescents:
      • 200 mg daily up to 30 minutes before eating a meal that may cause heartburn (the maximum daily dose is 400 mg/day)
  • For the relief of symptoms:
    • Children older than 12 years and Adolescents:
      • 200 mg daily to a maximum daily dose of 400 mg/day.

 

Pregnancy Risk Factor B

  • Although Cimetidine crosses into the placenta, adverse reactions have not been reported. 
  • H2 blockers can be used to treat gastroesophageal and duodenal ulcers, GERD, and gastric reflux disease (GERD) during pregnancy.

Use of Tagamet (Cimetidine), during breastfeeding

  • It is excreted in breastmilk. Cimetidine therapy is not recommended for breastfeeding.

Tagamet (Cimetidine) Dose in Kidney Disease:

  • Patient with a GFR of more than 50 mL/minute:
    • No dose adjustment required
  • Patient with GFR 10 to 50 mL/minute:
    • Administer half the normal dose
  • Patient with GFR of less than 10 mL/minute
    • 300 mg every twice or thrice daily
  • Hemodialysis:
    • Administer the dose after dialysis
  • Patients with CCRT:
    • Administer half the normal dose.
  • Peritoneal dialysis:
    • 300 mg twice or thrice daily.

Tagamet (Cimetidine) Dose in Liver Disease:

The manufacturer has not recommended any dose adjustment in patients with liver disease. However, it should be used with caution and dose adjustment may be necessary.

Common Side Effects of Tagamet (Cimetidine):

  • Central nervous system:
    • Headache
    • Dizziness
    • Drowsiness
    • Agitation
  • Endocrine & metabolic:
    • Gynecomastia
  • Gastrointestinal:
    • Diarrhea

 Less Common Side Effects:

  • Cardiovascular:
    • Atrioventricular block,
    • Bradycardia,
    • Hypotension,
    • Tachycardia,
    • Vasculitis
  • Central nervous system:
    • Confusion,
    • Decreased sexual activity
  • Dermatologic:
  • Gastrointestinal:
    • Nausea,
    • Pancreatitis,
    • Vomiting
  • Genitourinary:
    • Breast swelling
  • Hematologic & oncologic:
    • Agranulocytosis,
    • Aplastic anemia,
    • Hemolytic anemia
    • Neutropenia,
    • Pancytopenia,
    • Thrombocytopenia
  • Hepatic:
    • Hepatic fibrosis
    • Increased serum ALT,
    • Increased serum AST
  • Hypersensitivity:
    • Anaphylaxis
  • Neuromuscular & skeletal:
    • Arthralgia,
    • Myalgia,
    • Polymyositis
  • Renal:
    • Increased serum creatinine,
    • Interstitial nephritis
  • Respiratory:
    • Pneumonia
  • Miscellaneous:
    • Fever

 

Contraindication to Tagamet (Cimetidine) include:

  • Allergy or intolerance to Cimetidine or any other component of the formulation
  • It shouldn't be mixed with any other antacids
  • OTC labeling should not be used for self-medication.
    • When swallowing is difficult or painful
    • Black stool, bloody vomit
    • Allergy or sensitivity to cimetidine and other acid reducers

Warnings and Precautions

  • Confusion
    • Patients with liver disease and renal disease, as well as patients who are elderly or severely ill, may occasionally experience confusion.
  • Vitamin B deficiencies:
    • Malabsorption may result from prolonged use of Cimetidine for longer than 2 years. __S.11__
  • Gastric cancer:
    • This may mask symptoms of gastric cancer.
  • Hepatic impairment
    • Patients suffering from liver disease should be cautious when using it
  • Renal impairment
    • It should be used with caution in patients with impaired renal function. Cimetidine can cause false interpretations of creatinine levels.
  • OTC labeling
    • If you use OTC self-medication for self-treatment, notify your healthcare provider immediately if your symptoms get worse or if it lasts more than two weeks. If any of these symptoms are present, it should be avoided.
      • Pain in the chest
      • Wheezing
      • Nausea and vomiting
      • Unexplained weight loss
      • Stomach pain
      • Heartburn that lasts longer than 3 months
      • Heartburn and dizziness, or sweating
      • Dyspnea can cause chest pain or shoulder pain.
      • Sweating and pain that spreads to the arms, neck, or shoulders

Cimetidine: Drug Interaction

Note: Drug Interaction Categories:

  • Risk Factor C: Monitor When Using Combination
  • Risk Factor D: Consider Treatment Modification
  • Risk Factor X: Avoid Concomitant Use

Risk Factor C (Monitor therapy).
Alfentanil Cimetidine can increase the serum level of Alfentanil.
ARIPiprazole CYP3A4 Inhibitors, Weak, may increase serum levels of ARIPiprazole. Monitoring for increased aripiprazole-pharmacologic effects is important. Aripiprazole dosage adjustments may be necessary depending on the indication and/or concomitant therapy. For more information, consult the full interaction monograph.
ARIPiprazole CYP2D6 inhibitors (Weak), may increase serum levels of ARIPiprazole. Monitoring for increased aripiprazole-pharmacologic effects is important. Aripiprazole dosage adjustments may be necessary depending on the indication and/or concomitant therapy. For more information, consult the full interaction monograph.
AtorvaSTATin Could increase the toxic/adverse effects of Cimetidine. There is the potential to increase endogenous steroid activity by using Cimetidine.
Azelastine Systemic Cimetidine can increase serum Azelastine (Systemic) concentrations.
Capecitabine Cimetidine can increase serum levels of active metabolites of Capecitabine. Particularly, fluorouracil concentrations may increase.
CarBAMazepine Cimetidine can increase CarBAMazepine serum concentrations. One week after starting cimetidine, the serum carbamazepine level may return to normal.
Carvedilol Cimetidine can increase Carvedilol's serum concentration.
Cefpodoxime Cefpodoxime may be less absorbed by histamine H2 receptor antagonists. Separate oral doses for at least 2 hours
Chlormethiazole Cimetidine can increase the serum level of Chlormethiazole.
Chloroquine Cimetidine can increase Chloroquine serum concentrations.
Citalopram Cimetidine can increase Citalopram's serum concentration.
Systemic Cysteamine Histamine H2 Receptor Anagonists can reduce the therapeutic effects of Cysteamine Systemic.
Dalfampridine Cimetidine can increase the serum concentrations of Dalfampridine. Management: There are many differences in international recommendations regarding the concomitant administration of dalfampridine (also known as fampridine here in Canada) or cimetidine. Refer to appropriate product labeling.
Dexmethylphenidate Dexmethylphenidate may be absorbed more efficiently by histamine H2 receptor antagonists. H2-antagonists can interfere with the normal release from extended-release capsules (FocalinXR brand), which could lead to both an increase in absorption (early and delayed)
Doxofylline Doxofylline serum concentration may be increased by Cimetidine
Erdafitinib Increased serum concentrations of P-glycoprotein/ABCB1 Substrates may be possible.
Erdafitinib May increase serum OCT2 Substrates concentrations.
Escitalopram Cimetidine can increase serum Escitalopram concentrations.
Flibanserin Flibanserin may be increased by CYP3A4 inhibitors (Weak).
Floxuridine Cimetidine can increase serum levels of Floxuridine's active metabolite(s). Fluorouracil concentrations may increase.
Flunitrazepam Cimetidine can increase Flunitrazepam's serum concentration.
Fluorouracil Systemic Fluorouracil (Systemic) may be increased by Cimetidine.
FLUoxetine Cimetidine can increase FLUoxetine serum concentrations.
Fosamprenavir Fosamprenavir serum concentration may be decreased by histamine H2 receptor antagonists. Cimetidine can also be used to inhibit the metabolism active metabolite Amprenavir. This may make its effects on fosamprenavir/amprenavir concentrations more difficult to predict.
Indinavir Indinavir serum concentration may be decreased by histamine H2 receptor antagonists
Iron Salts Iron salts absorption may be decreased by histamine H2 receptor antagonists. Exceptions: Ferric Carboxymaltose, Ferric Citrate, Ferric Gluconate and Ferric Gluconate. Ferric HydroxidePolymaltose Complex. Ferric Pyrophosphate Citrate. Ferumoxytol. Iron Dextran Complex. Iron Isomaltoside. Iron Sucrose.
Lumacaftor May lower the serum concentrations of P-glycoprotein/ABCB1 Substrates. Lumacaftor could increase serum levels of P-glycoprotein/ABCB1 Substrates.
Mebendazole Cimetidine can increase serum Mebendazole concentrations.
Melatonin Cimetidine can increase serum levels of Melatonin.
Meperidine Cimetidine can increase the serum concentrations of Meperidine.
Methylphenidate The absorption of Methylphenidate may be increased by histamine H2 receptor antagonists. H2-antagonists can interfere with the normal release from extended-release capsules (Ritalin LA) of Methylphenidate. This could lead to both an increased (early) or decreased (later) absorption.
Mirtazapine Cimetidine can increase Mirtazapine's serum concentration.
Multivitamins/Minerals with ADEK Folate Iron Histamine H2 Receptor Antagonists can decrease serum concentrations of Multivitamins/Minerals (with ADEK Folate, Iron). H2-antagonists may impair iron absorption.
Nelfinavir Nelfinavir serum concentration may be decreased by histamine H2 receptor antagonists. It is possible that the concentrations of active M8 metabolites may be decreased.
Nicotine Cimetidine can increase Nicotine serum concentrations.
PARoxetine Cimetidine can increase serum PARoxetine concentrations.
Pentoxifylline Pentoxifylline serum concentrations may be increased by Cimetidine.
Perhexiline Perhexiline serum concentration may be increased by CYP2D6 inhibitors (Weak).
P-glycoprotein/ABCB1 Inducers The serum concentrations of Pglycoprotein/ABCB1 Substrates may be decreased. Inducers of pglycoprotein may limit the distribution to certain cells/tissues/organs in which p-glycoprotein exists in high amounts (e.g. brain, T-lymphocytes and testes). .
Inhibitors of P-glycoprotein/ABCB1 Increases serum concentrations of Pglycoprotein/ABCB1 substrates. P-glycoprotein inhibitors can also increase the distribution of pglycoprotein substrates to certain cells/tissues/organs in which p-glycoprotein exists in high amounts (e.g. brain, testes and T-lymphocytes). .
Pilsicainide Cimetidine can increase the serum level of Pilsicainide.
Pramipexole Pramipexole may be increased by Cimetidine.
Praziquantel Praziquantel may be increased by Cimetidine.
Propafenone Cimetidine can increase Propafenone's serum concentration.
Ranolazine Increased serum concentrations of P-glycoprotein/ABCB1 Substrates may be possible.
Roflumilast Cimetidine can increase the serum concentrations for active metabolites of Roflumilast. Roflumilast serum concentration may be increased by Cimetidine
Saquinavir Saquinavir may be increased by an antagonist of the histamine H2 receptor.
Sulfonylureas Cimetidine can increase serum levels of sulfonylureas.
Tamsulosin Cimetidine can increase Tamsulosin serum concentrations.
Tegafur Cimetidine can increase serum levels of active metabolites of Tegafur. Fluorouracil concentrations may increase.
Teriflunomide May increase serum OAT3 Substrates concentrations.
Tricyclic Antidepressants Cimetidine could decrease the metabolism Tricyclic Antidepressants.
Urapidil Cimetidine could increase the hypotensive effects of Urapidil.
Varenicline Varenicline serum concentration may be increased by histamine H2 receptor antagonists. Monitoring: Watch for elevated varenicline adverse reactions when concomitant treatment with cimetidine and other H2-antagonists is done, especially in patients with severe kidney impairment. There are many international product labeling guidelines. Refer to appropriate labeling.
Velpatasvir Velpatasvir serum concentration may be decreased by an antagonist of the histamine H2 receptor.

Risk Factor D (Consider therapy modifications)

  
Acalabrutinib Acalabrutinib serum concentration may be decreased by histamine H2 receptor antagonists. Management: Acalabrutinib should be administered separately to reduce the possibility of an interaction. This is done by giving it 2 hours before you take a histamine-2 receptor antagonist.
Amiodarone Cimetidine can increase Amiodarone's serum concentration. Management: Look for alternatives to Cimetidine. Monitor for increased amiodarone levels/effects during cimetidine initiation/dose rise or decreased concentrations/effects after cimetidine discontinuation/dose drop.
Atazanavir The serum concentration of Atazanavir may be decreased by using an antagonist of histamine H2 receptors. Management: There are specific dosage limitations and administration guidelines. Please consult the full interaction monograph and atazanavir prescribing info.
Bosutinib Bosutinib serum concentration may be decreased by histamine H2 receptor antagonists. Administration: Do not take histamine H2 receptor antagonists for more than two hours prior to or after bosutinib.
Bromazepam Bromazepam serum concentration may be increased by Cimetidine. Management: Bromazepam may be used with an H2-antagonist (e.g. ranitidine) that is not potent CYP inhibitor. Alternately, cimetidine could be used with a benzodiazepine (e.g. lorazepam) that does not undergo oxidative metabolic.
Calcium Channel Blockers Cimetidine can increase serum calcium channel blockers. Management: Look for alternatives to Cimetidine. Monitor for calcium channel blocker effects after cimetidine dose increase/initiation, or decreased effects after cimetidine stoppage/dose decrease. Clevidipine, AmLODIPine, NiCARdipine are exceptions.
Carmustine Cimetidine could increase the myelosuppressive effects of Carmustine. Treatment: If you are taking carmustine, consider other options. Monitor for increased carmustine myelotoxicity if the combination is not possible.
Cefditoren The serum concentration of Cefditoren may be decreased by histamine H2 receptor antagonists. Cefditoren is not recommended to be taken with H2-antagonists or antacids. If H2-antagonists are not an option, consider other methods of controlling acid reflux such as diet modification or antimicrobial therapy.
Cilostazol CYP2C19 inhibitors may cause an increase in Cilostazol serum concentration. Treatment: Patients who are receiving CYP2C19 inhibitors should reduce their cilostazol dosage to 50mg twice daily.
Cisapride Cimetidine can increase Cisapride serum concentrations. Management: Look for alternatives to Cimetidine. This combination should not be used. Monitor for toxic effects of Cimetidine if it is administered or increased in dose. If cimetidine has been discontinued or reduced in dosage, this will also alert you to potential side effects.
CloZAPine CloZAPine serum concentration may be increased by Cimetidine. Management: You may consider using an alternative H2 antagonist. If clozapine is started or dose increased, monitor for any increased toxic effects.
Dacomitinib The serum concentration of Dacomitinib may be decreased by histamine H2 receptor antagonists. Administration: Take dacomitinib 6 hours or more before or after a histamine H2-receptor antagonist H2RA (H2RA).
Erlotinib The serum concentration of Erlotinib may be decreased by histamine H2 receptor antagonists. Patients receiving erlotinib should avoid H2-antagonists whenever possible. Concomitant treatment should not be attempted if possible. Erlotinib should only be administered once daily, at least 10 hours after, and no more than 2 hours before, H2-antagonist therapy.
Fosphenytoin -Phenytoin Cimetidine could increase the toxic/adverse effects of FosphenytoinPhenytoin. Cimetidine can increase serum FosphenytoinPhenytoin concentrations. To avoid the interaction, you may want to use an alternative H-antagonist. If cimetidine dose is increased or initiated, monitor for toxic effects.
Gefitinib Gefitinib serum concentration may be decreased by histamine H2 receptor antagonists. Gefitinib Administration: Give gefitinib at the minimum 6 hours prior to or after administering a histamine-H2-antagonist. Monitor your clinical response to gefitinib.
Itraconazole The serum concentration of Itraconazole may be increased by histamine H2 Receptor Antagonists. The serum concentration of Itraconazole may be decreased by histamine H2 receptor antagonists. Sporanox brand Itraconazole should be administered at least 2 hours prior to or 2 hours after the administration of any histamine antagonist H2 receptor antagonists (H2RAs). Itraconazole dosage reduction may be possible if you are exposed to Tolsura brand itraconazole.
Ketoconazole Systemic The serum concentration of Ketoconazole may be decreased by using an antagonist to the Histamine H2 receptor. Administration: Take oral ketoconazole 2 hours before using any H2-receptor antagonist. Watch out for any signs that indicate an insufficient clinical response to ketoconazole.
Ledipasvir The serum concentration of Ledipasvir may be decreased by an antagonist of the Histamine H2 receptor.
Lomitapide Lomitapide may be increased by CYP3A4 inhibitors (Weak). Patients taking lomitapide 5 mg/day can continue to take this dose. Patients who are taking lomitapide 10mg/day or more must reduce their lomitapide dosage by half. You can then adjust the lomitapide dose to 30 mg/day for adults.
Mesalamine Mesalamine may be less effective if it is ingested by Histamine H2 Receptor Antagonists. Histamine H2-Antagonist-mediated changes in gastrointestinal pH can lead to the premature release mesalamine from certain sustained-release mesalamine drugs. Management: Avoid concurrent administration of high doses of histamine H2-receptor antagonists and sustained-release mesalamine product.
MetFORMIN Cimetidine can increase MetFORMIN serum concentrations. Management: Patients receiving Metformin should consider alternatives to Cimetidine due to the possibility of increased metformin levels and toxicities (including lactic acidosis).
Moclobemide Moclobemide metabolism may be affected by Cimetidine. To avoid the interaction, you may want to consider other agents that lower your gastric pH. Combining moclobemide is recommended to reduce the dose by 50%. Patients should be closely monitored for any increased moclobemide toxicities.
Nilotinib The serum concentration of Nilotinib may be decreased by histamine H2 receptor antagonists. To minimize the chance of an interaction, the nilotinib dose must be administered 10 hours after or two hours before the antagonist to the H2 receptor.
Posaconazole Posaconazole serum concentrations could be decreased by histamine H2 receptor antagonists. Administration: If possible, avoid concurrent oral suspensions with H2-antagonists. If this combination is being used, monitor patients carefully for any decreased antifungal effects. It is possible that delayed-release posaconazole tablets will interact less.
Procainamide Cimetidine can increase Procainamide serum concentrations. Treatment: Patients taking procainamide should consider a different H2-receptor antagonist. Monitor for procainamide's toxic/therapeutic effects if combined.
QuiNIDine Cimetidine can increase QuiNIDine serum concentrations. Management: Look for alternatives to cimetidine. Monitor for elevated quinidine levels/toxicity and cimetidine discontinuation/dose reduction.
QuiNINE Cimetidine can increase QuiNINE's serum concentration.
Ilpivirine Rilpivirine serum concentration may be decreased by histamine H2 receptor antagonists. Treatment: Take histamine H2 receptor antagonists no less than 12 hours before or after taking rilpivirine.
Secretin Secretin's diagnostic effectiveness may be diminished by the use of H2 Receptor Antagonists for histamine. Use of H2-Antagonists can cause gastrin secretion to increase in response to secretin stimulation, which could falsely suggest gastrinoma. Management: It is important to avoid the simultaneous use of secretin and histamine H2-antagonists. Stop using H2RAs at the very least two days before secretin administration.
Tafenoquine Increased serum concentrations of OCT2 Substrates. Management: Do not use OCT2 Substrates with tafenoquine. If the combination is impossible to avoid, then monitor for signs of toxic effects and consider taking a lower dose of OCT2 Substrates according to the labeling.
Theophylline Derived Cimetidine can decrease metabolism of Theophylline derivatives. Dyphylline is an exception.
TiZANidine CYP1A2 Inhibitors, Weak, may increase serum TiZANidine concentrations. These combinations should be avoided whenever possible. Begin tizanidine in adults at 2 mg. Then, increase the dose according to patient response. Be aware of any adverse reactions and increased effects of tizanidine.
Tolvaptan May increase serum OAT3 Substrates concentrations.
Vitamin K antagonists (eg warfarin). Vitamin K Antagonists may have an anticoagulant effect that Cimetidine might enhance.
Zaleplon Cimetidine can increase serum levels of Zaleplon. Patients taking cimetidine should limit their initial dose to 5 mg. When these agents are combined, monitor patients for any increased zaleplon toxicities/effects (ie, sedation or CNS depression).
ZOLMitriptan Cimetidine can increase ZOLMitriptan's serum concentration. Management: When administered with cimetidine, limit the daily intake of zolmitriptan at 2.5 mg.

Risk Factor X (Avoid Combination)

  
Cefuroxime The absorption of Cefuroxime may be decreased by the use of histamine H2 receptor antagonists. Separate oral doses for at least 2 hours
Dasatinib Histamine H2 Receptor Antagonists can decrease the absorption rate of Dasatinib. If you require acid-reducing therapy, you can use antacids (2 hours before or 2 hours after Dasatinib administration).
Delavirdine The serum concentration of Delavirdine may be decreased by histamine H2 receptor antagonists. Patients receiving delavirdine should avoid chronic therapy with H2-antagonists. Although the clinical relevance of H2-antagonist therapy with Delavirdine for short-term is not known, it should be done with caution.
Dofetilide Cimetidine can increase Dofetilide's serum concentration. This can be due to dofetilide metabolism inhibition and dofetilide renal tubular secretion inhibition.
EpiRUBicin Cimetidine can increase EpiRUBicin serum concentrations.
Neratinib Cimetidine could increase the serum level of Neratinib. Cimetidine could decrease the serum level of Neratinib. Cimetidine, in particular, may decrease neratinib sorption. Management: Avoid concomitant neratinib/cimetidine use.
PAZOPanib The serum concentration of PAZOPanib may be decreased by histamine H2 receptor antagonists. Avoid using histamine H2-antagonists with pazopanib. There are no strategies to reduce the interaction between these agents (e.g., dose separation).
Pimozide Pimozide may be increased by CYP3A4 inhibitors (Weak).
Risedronate Risedronate serum concentrations could be increased by histamine H2 receptor antagonists. This is especially true for delayed-release risedronate.

Monitoring Parameters:

  • CBC
  • Gastric pH
  • Renal functions
  • Occult blood in patients with GI bleeding, and
  • Signs of confusion.

How to take Tagamet (Cimetidine)?

It may be taken with meals. In critically ill patients, it can be administered via NG tube 

Mechanism of Action of Tagamet (Cimetidine):

Cimetidine inhibits competitively histamine receptors in the gastric mucosa. This results in suppression of gastric acid production and volume.

TheStart of actionIt takes one hour to complete theDuration of the actionIt takes 4 to 5 hours. (80% of the gastric acid secretion can be suppressed).

 It isRapidly absorbed20% protein bound

It is only partiallyMetabolizedThe liver is responsible for generating the aforementioned.

bioavailability60% - 70% 

TheEliminating half-lifeIn neonates, it is 3.6 hours. Children and adolescents are 1.39 hours. Adults are 2 hours.

The time to Peak serum is possibleConcentration is between 0.75 and 1.5 hours.

It is primarilyExcretedVia urine

International Brands of Tagamet (Cimetidine)

  • APO-Cimetidine
  • DOM-Cimetidine
  • MYLAN-Cimetidine
  • NOVO-Cimetine
  • PMS-Cimetidine
  • Aci-Med
  • Acidnor
  • Aciloc
  • Acinil
  • Alcatex
  • Altramet
  • Apo-Cimetidine
  • Belomet
  • Benomet
  • Brumetidina
  • Campanex
  • Cementin
  • Cencamat
  • Cidine
  • Cimbene
  • Cimedine
  • Cimehexal
  • Cimeldine
  • Cimet
  • Cimetag
  • Cimetase
  • Cimetid
  • Cimetidin
  • Cimetidin AL
  • Cimetidina
  • Cimetin
  • Cimewell
  • Cimex
  • Cimexol
  • CimLich
  • Cimulcer
  • Cinadine
  • Cintag
  • Cismetin
  • Citidine
  • Citius
  • Cytine
  • Defense
  • Dispamet
  • Ficimet
  • Gadol
  • Gastrodin
  • Gawei
  • Gerucim
  • Getidin  H- 2
  • H2 Blocker-ratiopharm
  • Haldin
  • Hexamet
  • Himentin
  • Histodil
  • Histodil[inj.]
  • Iwamet
  • Lenamet
  • Lock 2
  • Magicul
  • Manomet
  • Neutronorm
  • Nuardin
  • Powegon
  • Sanmetidin
  • Secapine
  • Shintamet
  • Siamidine
  • Stogamet
  • Stomedine
  • Stomet
  • Tagamet
  • Tamex
  • Tenomet
  • Timet
  • Ulcedin
  • Ulcerfen
  • Ulcerid
  • Ulcerin
  • Ulcidine
  • Ulcim
  • Ulcomedina
  • Ulcomet
  • Ulsikur
  • Ultipus
  • Weisdin
  • Xepamet

Tagamet (Cimetidine) Brands in Pakistan:

Cimetidine (HCl) [Inj 100 mg/ml]
ALTRAMET NOVARTIS PHARMA (PAK) LTD
CIMEPHA EPHARM LABORATORIES
CIMETAMAT INDUS PHARMA (PVT) LTD.
MB-CIDINE MULTINATIONAL BUISNESS LINK
MINATIDINE ELITE PHARMA
TAGAMET GLAXOSMITHKLINE
ULCEMET SIZA INTERNATIONAL (PVT) LTD.
ULCEREX SAMI PHARMACEUTICALS (PVT) LTD.

 

Cimetidine (HCl) [Inj 200 mg/ml]
DISPIDINE SWISS PHARMACEUTICALS (PVT) LTD.
GASTRAMED MEDICAIDS PAKISTAN (PVT) LTD.
UL-GET SAYDON PHARMACEUTICAL INDUSTRIES (PVT) LTD.

 

Cimetidine (HCl) [Susp 100 mg/10ml]
ACIMET BLOOM PHARMACEUTICALS (PVT) LTD.
BACIMET DAVIS PHARMACEUTICAL LABORATORIES
CIMESCOT SCOTMANN PHARMACEUTICALS
CIMET FEROZSONS LABORATOIES LTD.
CIMETAMAT INDUS PHARMA (PVT) LTD.
CITADINE MEDICEENA PHARMA (PVT) LTD.
DRAPE LIBRA PHARMACEUTICALS (PVT) LTD
DYSPAMET GLAXOSMITHKLINE
ENDONIL WERRICK PHARMACEUTICALS
GASOPEL SYNCHRO PHARMACEUTICALS
KEMYREX ALKEMY PHARMACEUTICAL LABORATORIES (PRIVATE) LTD.
MB-CIDINE MULTINATIONAL BUISNESS LINK
MEDI CIM MAC & RANS PHARMACEUTICALS (PVT) LTD
NEUCIMET NEUTRO PHARMA (PVT) LTD.
NORMACID WILSONS PHARMACEUTICALS
PEPTIMAX FOZAN PHARMACEUTICALS INDUSTRIERS (PVT) LTD
ULCEREX SAMI PHARMACEUTICALS (PVT) LTD.

 

Cimetidine (HCl) [Susp 200 mg/10ml]
ACIDIL IRZA PHARMA (PVT) LTD.
ULCEREX SAMI PHARMACEUTICALS (PVT) LTD.
ULCEROC MEDICEENA PHARMA (PVT) LTD.

 

Cimetidine (HCl) [Tabs 200 mg]
ACIDIL IRZA PHARMA (PVT) LTD.
ACIDIL IRZA PHARMA (PVT) LTD.
AGAMID PHARMAWISE LABS. (PVT) LTD.
ALTRAMET NOVARTIS PHARMA (PAK) LTD
BACIMET DAVIS PHARMACEUTICAL LABORATORIES
CEMETAWIN JINNAH PHARMACEUTICALS
CIMETAI ALSON PHARMACEUTICALS
CIMETAMAT INDUS PHARMA (PVT) LTD.
CIMETIDINE NAWABSONS LABORATORIES (PVT) LTD.
CINIL KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS
CITAMAT KARACHI CHEMICAL INDUSTRIES
DOSAMET DOSACO LABORATORIES
DOZAMET CHAS. A. MENDOZA
DRAPE LIBRA PHARMACEUTICALS (PVT) LTD
HEALET PARAMOUNT PHARMACEUTICALS
MB-CIDINE MULTINATIONAL BUISNESS LINK
PHARDINE PHARMACARE LABORATORIES (PVT) LTD.
RAKAMET RAKAPOSHI PHARMACEUTICAL (PVT) LTD.
RESCAMET RASCO PHARMA
SEMIDINE UNEXO LABS (PVT) LTD.
STOMACURE SHAWAN PHARMACEUTICALS
TAGAMET GLAXOSMITHKLINE
ULCELOC BOSCH PHARMACEUTICALS (PVT) LTD.
ULCEMET SIZA INTERNATIONAL (PVT) LTD.
ULCERINE GEOFMAN PHARMACEUTICALS
ULCET CONSOLIDATED CHEMICAL LABORATORIES (PVT) LTD.
VASIMET VALOR PHARMACEUTICALS
VEGAMET VENUS PHARMA
WILLCIMET WILSHIRE LABORATORIES (PVT) LTD.
ZEMET ZEPHYR PHARMATEC (PVT) LTD.

 

Cimetidine (HCl) [Tabs 400 mg]
ACIDIL IRZA PHARMA (PVT) LTD.
ACIDIL IRZA PHARMA (PVT) LTD.
ACIMET BLOOM PHARMACEUTICALS (PVT) LTD.
AGAMID PHARMAWISE LABS. (PVT) LTD.
ALCIDE ALSON PHARMACEUTICALS
ALMIT WEBROS PHARMACEUTICALS
ALTRAMET NOVARTIS PHARMA (PAK) LTD
BACIMET DAVIS PHARMACEUTICAL LABORATORIES
CEMETAWIN JINNAH PHARMACEUTICALS
CID ZESION PHARMACEUTICAL (PVT) LTD
CIMESCOT SCOTMANN PHARMACEUTICALS
CIMET FEROZSONS LABORATOIES LTD.
CIMETAMAT INDUS PHARMA (PVT) LTD.
CIMETOGEN GENERA PHARMACEUTICALS
CIMIRAX UMERSONS
CIMSER PANACEA PHARMACEUTICALS
CINIL KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS
CITAMAT KARACHI CHEMICAL INDUSTRIES
CONTRACID MEDERA PHARMACEUTICALS (PVT) LTD.
DOSAMET DOSACO LABORATORIES
DOZAMET CHAS. A. MENDOZA
DRAPE LIBRA PHARMACEUTICALS (PVT) LTD
ENDONIL WERRICK PHARMACEUTICALS
EROMET FORTE EROS PHARMACEUTICALS
FITIDINE FYNK PHARMACEUTICALS
FOVOMET FLOW PHARMACEUTICALS (PVT) LTD.
GASTRAMED MEDICAIDS PAKISTAN (PVT) LTD.
HEALET PARAMOUNT PHARMACEUTICALS
HIMETIDIN HELIX PHARMA (PRIVATE) LIMITED
MB-CIDINE MULTINATIONAL BUISNESS LINK
NORMACID WILSONS PHARMACEUTICALS
PHARDINE PHARMACARE LABORATORIES (PVT) LTD.
RAKAMET RAKAPOSHI PHARMACEUTICAL (PVT) LTD.
REMOCEMIDINE SYNTEX PHARMACEUTICALS
SEMAG REMINGTON PHARMACEUTICAL INDUSTRIES (PVT) LTD.
SEMIDINE UNEXO LABS (PVT) LTD.
STOMACURE SHAWAN PHARMACEUTICALS
SWAYMET ARDIN PHARMACEUTICALS
T-DINE GABA PHARMACEUTICALS LABS
TAGACIT TAGMA PHARMA (PVT) LTD.
TAGAMET GLAXOSMITHKLINE
TIMIT ALLIANCE PHARMACEUTICALS (PVT) LTD.
UL-GET SAYDON PHARMACEUTICAL INDUSTRIES (PVT) LTD.
ULCELOC BOSCH PHARMACEUTICALS (PVT) LTD.
ULCEMET SIZA INTERNATIONAL (PVT) LTD.
ULCEREX SAMI PHARMACEUTICALS (PVT) LTD.
ULCERINE GEOFMAN PHARMACEUTICALS
ULCET CONSOLIDATED CHEMICAL LABORATORIES (PVT) LTD.
VASIMET VALOR PHARMACEUTICALS
VEGAMET VENUS PHARMA
VENOPAX EVRON (PVT) LTD.
WILLCIMET WILSHIRE LABORATORIES (PVT) LTD.
ZEMET ZEPHYR PHARMATEC (PVT) LTD.

 

Cimetidine (HCl) [Tabs 800 mg]
ALTRAMET NOVARTIS PHARMA (PAK) LTD
CIMESCOT SCOTMANN PHARMACEUTICALS
NORMACID WILSONS PHARMACEUTICALS
Recent Posts
  • Finerenone: A Promising Treatment for Diabetic Kidney Disease and Heart Failure
    17-09-2024
  • Ensifentrine (OHTUVAYRE) for COPD: Complete FDA Prescribing Guide
    06-09-2024
  • Fitness and Nutrition: A Holistic Approach to Diabetes Management
    03-09-2024
  • YORVIPATH (palopegteriparatide) Injection for Hypoparathyroidism: FDA Prescribing Information
    29-08-2024

Comments

NO Comments Found

Related Posts
Benefiber (Wheat dextrin) Sachet and Tablets
13-12-2021
Xermelo (Telotristat ethyl) - Uses, Dose, MOA, Brands, Side effects
13-12-2021
Teduglutide (Gattex) - a GLP-2 analog
13-12-2021
Zelnorm (Tegaserod) - Complete Drug Information
13-12-2021